Cite
Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer.
MLA
Finnegan, Ellen, et al. “Complexation of Histone Deacetylase Inhibitor Belinostat to Cu(II) Prevents Premature Metabolic Inactivation in Vitro and Demonstrates Potent Anti-Cancer Activity in Vitro and Ex Vivo in Colon Cancer.” Cellular Oncology (2211-3428), vol. 47, no. 2, Apr. 2024, pp. 533–53. EBSCOhost, https://doi.org/10.1007/s13402-023-00882-x.
APA
Finnegan, E., Ding, W., Ude, Z., Terer, S., McGivern, T., Blümel, A. M., Kirwan, G., Shao, X., Genua, F., Yin, X., Kel, A., Fattah, S., Myer, P. A., Cryan, S.-A., Prehn, J. H. M., O’Connor, D. P., Brennan, L., Yochum, G., Marmion, C. J., & Das, S. (2024). Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer. Cellular Oncology (2211-3428), 47(2), 533–553. https://doi.org/10.1007/s13402-023-00882-x
Chicago
Finnegan, Ellen, Wei Ding, Ziga Ude, Sara Terer, Tadhg McGivern, Anna M. Blümel, Grainne Kirwan, et al. 2024. “Complexation of Histone Deacetylase Inhibitor Belinostat to Cu(II) Prevents Premature Metabolic Inactivation in Vitro and Demonstrates Potent Anti-Cancer Activity in Vitro and Ex Vivo in Colon Cancer.” Cellular Oncology (2211-3428) 47 (2): 533–53. doi:10.1007/s13402-023-00882-x.